# Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

> **NCT06927635** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 75 (estimated)

## Conditions studied

- Castrate Resistance Prostate Cancer
- OligoProgressive Metastatic Disease

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)
- **OTHER:** Systemic therapy

## Key facts

- **NCT ID:** NCT06927635
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927635, "Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06927635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*